• Patents cover a polymorph (crystalline form) of PTD802, Pheno’s lead clinical candidate, and a composition of matter covering PTD939, Pheno’s second GPR17 antagonist
  • PTD802, a small molecule therapeutic designed to promote remyelination in neurological and neurodegenerative diseases such as multiple sclerosis, has both UK MHRA CTA and US FDA IND clearance for clinical study

Edinburgh, UK, 18 November 2026: Pheno Therapeutics Limited. (Pheno), a clinical stage biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological and neurodegenerative diseases, today announced it has been granted two key patents protecting its selective GPR17 (G protein-coupled receptor 17) antagonist pipeline.

Patent GB2642355 covers a polymorph (crystalline form) of PTD802, the specific form of Pheno’s lead clinical candidate being taken into the clinic, extending protection beyond existing patents. This adds further protection alongside existing UCB patents exclusively licensed to Pheno, which provide composition-of-matter protection for PTD802 in many countries worldwide. Patent GB2700773 covers a composition of matter IP for PTD939, the Company’s second programme. Both PTD802 and PTD939 are GPR17 antagonists. The PTD939 composition of matter patent is the strongest form of protection for a new drug, securing the programme as it enters IND-enabling studies, initially targeting amyotrophic lateral sclerosis.

PTD802 is a novel small molecule therapeutic designed to promote remyelination, with an initial focus on multiple sclerosis (MS), a neurological disease with high unmet medical need. The Company has already achieved clinical trial authorisation (CTA) from the UK’s MHRA1 and Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA)2 for PTD802, giving clearance to proceed to the clinic in both the UK and the US. Developed under an exclusive worldwide licence from UCB, PTD802 is the first GPR17 programme to receive IND clearance, with the potential to deliver a new class of neuroprotective therapeutics. The first-in-human study, due to commence in Q4 2026, will evaluate safety and tolerability in healthy volunteers.

Fraser Murray, PhD, CEO, Pheno Therapeutics, said: “We are building a strong, layered IP position around GPR17 with two protected assets, one of which is already cleared for clinical study in the UK and US. The chemistry and development work carried out by the Pheno team has been instrumental in the success of these patent applications, which will now go on to support the long-term value of the pipeline. We look forward to providing further updates as we progress PTD802 to a first-in-human trial.”

 Both patents, issued from priority patent applications based on which subsequent PCT applications were filed (PTD802 “Polymorph” WO2026/008995 and PTD939 “Compounds” WO2025/243046), which are currently undergoing preparation for national or regional filings in several key territories worldwide.

[1]: Press release (14th January 2026) Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802

[2]: Press release (22nd June 2026) Pheno Therapeutics granted FDA IND clearance for lead multiple sclerosis therapeutic candidate PTD802